European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults

GSK, UK Dementia Research Institute and Health Data Research UK to collaborate on first-of-its-kind dementia research initiative

The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies

Merck and Zebra Technologies collaborate to create safety and traceability solutions

Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems

Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital

The freshly infused capital will primarily be deployed towards expansion and research & development

Cadila launches Cadilose for constipation and hepatic encephalopathy

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

J&J to break ground on new biologics facility in North Carolina

New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases

BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK

PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions

Indegene launches new center in London

USFDA grants Priority Review for new indication of finerenone for patients with common heart failure

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure